AstraZeneca

SASB Index Report 2020

This report is an index to the location of our disclosures that align with the Sustainability Accounting Standards Board (SASB) standards for Biotechnology & Pharmaceuticals. This is our first annual SASB Index Report and we expect to evolve our publications over time. The report provides data from 1 January 2020 to 31 December 2020, unless otherwise stated.

We continue to share other aspects of our sustainability in our online resources:

- 2020 Sustainability Report: describes our progress and challenges in our commitment to sustainability performance
- Sustainability Data Summary: provides performance measures and targets with at least three years of data where available
- 2020 Annual Report and Form 20-F: includes how sustainability is integrated across our business model and into risk management
- Sustainability webpages: cover additional topics of interest to our stakeholders
- Infographics: show our processes and practices
- Policies and company standards: state our position and guidance on key subjects

SASB INDEX

Metric Code	Metric	Disclosure Location
Safety of Clinical Trial Participants		
HC-BP-210a.1	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	Annual Report, p. 54 Global Standard: Bioethics, pp.4-7
HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2)Official Action Indicated (OAI)	2018: VAI - 2, OAI - 0 2019: VAI - 0, OAI - 0 2020: VAI - 0, OAI - 0
HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	Not reported
Access to Medicines		
HC-BP-240a.	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	Access to Medicine Index 2021 Report, pp. 136-139
HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	Not reported
Affordability and Pricing		
HC-BP-240b.1	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	Not reported
HC-BP-240b.2	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	Not reported
HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	Not reported
Drug Safety		
HC-BP-250a.1	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	FDA Adverse Event Reporting webpage
HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	FDA Adverse Event Reporting webpage
HC-BP-250a.3	Number of recalls issued, total units recalled	Sustainability Data Summary, p. 22
HC-BP-250a.4	Total amount of product accepted for take-back, reuse, or disposal	Not reported
HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	FDA - Inspection Citations FDA - Warning letters

SASB INDEX

Metric Code	Metric	Disclosure Location
Counterfeit Drugs		
HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	SASB response: Counterfeit drugs
HC-BP-260a.2	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	SASB response: Counterfeit drugs
HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	Not Reported
Ethical Marketing		
HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	Not Reported
HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	AstraZeneca Global Standard: Promoting our products
Employee Recruitment, Development and Retention		
HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	Sustainability Report, pp. 55-56
HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, (c) professionals, and (d) all others	Sustainability Data Summary, p. 17
Supply Chain Management		
HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	We do not use third-party auditing organisations, AstraZeneca has an internal risk based supplier assessment system. In 2020 Global Quality Audit completed 293 total audits consisting of 160 Vendor and General Service audits, 83 Contractor audits, 31 AstraZeneca internal audits and 19 Marketing Company audits
Business Ethics		
HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	Not Reported
HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	AstraZeneca and Global Transparency
Activity Metrics		
HC-BP-000.A	Number of patients treated	Epidemiology data Annual Report, p.10
HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	Annual Report, pp. 245-250